| Zacks Company Profile for Celularity, Inc. (CELU : NSDQ) |
|
|
| |
| • Company Description |
| Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK.
Number of Employees: 115 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.98 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 113,702 shares |
| Shares Outstanding: 32.45 (millions) |
| Market Capitalization: $31.73 (millions) |
| Beta: 0.77 |
| 52 Week High: $2.55 |
| 52 Week Low: $0.56 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-25.93% |
-25.15% |
| 12 Week |
43.78% |
40.27% |
| Year To Date |
-11.92% |
-15.50% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Robert J. Hariri - Chief Executive Officer and Chairman of the Board
John M. Sprague - Chief Financial Officer
Vincent LeVien - Director
Diane Parks - Director
Geoffrey Ling - Director
|
|
Peer Information
Celularity, Inc. (CORR.)
Celularity, Inc. (RSPI)
Celularity, Inc. (CGXP)
Celularity, Inc. (BGEN)
Celularity, Inc. (GTBP)
Celularity, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 151190204
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/13/26
|
|
Share - Related Items
Shares Outstanding: 32.45
Most Recent Split Date: 2.00 (0.10:1)
Beta: 0.77
Market Capitalization: $31.73 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 11/13/26 |
|
|
|
| |
